关键词： AAPC, Average annual percentage change ABIC, Age, Serum bilirubin, INR and serum Creatinine ABV, Alcohol by volume ALD, Alcohol-associated liver disease AUD, Alcohol use disorder BAC, Blood alcohol concentration CDC, Centers for Disease Control and Prevention COVID-19, Coronavirus disease 2019 GAHS, Glasgow alcoholic hepatitis score HE, Hepatic encephalopathy HRS, Hepatorenal syndrome ICD-10, International Classification of Diseases, 10th Edition MDF, Maddrey's Discriminant Function MELD, Model of end-stage liver disease MRI, Magnetic resonance imaging NHANES, National Health and Nutrition Examination Survey NIAAA, National Institute of Alcohol Abuse and Alcoholism NIS, National inpatient sample NSDUH, Annual National Survey on Drug Use and Health SAMHSA, Substance Abuse and Mental Health Services Administration US, United States USG, Ultrasonography WHO, World Health Organization YLD, Years of life lost to disability alcohol alcohol use disorder alcoholic cirrhosis alcoholic hepatitis alcoholic steatosis

来  源：   DOI：10.1016/j.jceh.2022.09.001   PDF(Pubmed)

Abstract：
Consumption of alcohol in excess leads to substantial medical, economic, and societal burdens. Approximately 5.3% of all global deaths may be attributed to alcohol consumption. Moreover, the burden of alcohol associated liver disease (ALD) accounts for 5.1% of all disease and injury worldwide. Alcohol use disorder (AUD) affects men more than women globally with significant years of life loss to disability in low, middle and well-developed countries. Precise data on global estimates of alcohol related steatosis, alcohol related hepatitis, and alcohol related cirrhosis have been challenging to obtain. In the United States (US), alcohol related steatosis has been estimated at 4.3% based on NHANES data which has remained stable over 14 years. However, alcohol-related fibrotic liver disease has increased over the same period. In those with AUD, the prevalence of alcohol related hepatitis has been estimated at 10-35%. Globally, the prevalence of alcohol-associated cirrhosis has been estimated at 23.6 million individuals for compensated cirrhosis and 2.46 million for those with decompensated cirrhosis. The contribution of ALD to global mortality and disease burden of liver related deaths is substantial. In 2016 liver disease related to AUD contributed to 50% of the estimated liver disease deaths for age groups 15 years and above. Data from the US report high cost burdens associated with those admitted with alcohol-related liver complications. Finally, the recent COVID-19 pandemic has been associated with marked increase in alcohol consumption worldwide and will likely increase the burden of ALD.
摘要：
过量饮酒会导致大量医疗，经济,和社会负担。全球约有5.3%的死亡可归因于饮酒。此外，酒精相关性肝病(ALD)的负担占全球所有疾病和损伤的5.1%.酒精使用障碍（AUD）在全球范围内影响男性比女性更大，中等和发达国家。关于酒精相关脂肪变性全球估计的精确数据，酒精相关性肝炎，和酒精相关的肝硬化一直是具有挑战性的获得。在美国（US），根据NHANES数据，酒精相关的脂肪变性估计为4.3％，该数据在14年中保持稳定。然而,与酒精相关的纤维化肝病在同一时期有所增加。在那些有AUD的人中，酒精相关肝炎的患病率估计为10-35%。全球范围内,对于代偿期肝硬化,酒精相关性肝硬化的患病率估计为2,360万人,失代偿期肝硬化的患病率为246万人.ALD对肝脏相关死亡的全球死亡率和疾病负担的贡献是巨大的。2016年，与AUD相关的肝病占15岁及以上年龄组估计肝病死亡人数的50％。来自美国的数据报告了与酒精相关的肝脏并发症相关的高成本负担。最后,最近的COVID-19大流行与全球酒精消费显著增加有关，并可能增加ALD的负担。
公众号